Novartis backs Zolgensma® to treat spinal muscular atrophy in children
Category: #health  By Mateen Dalal  Date: 2019-08-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis backs Zolgensma® to treat spinal muscular atrophy in children
  • Zolgensma is specifically designed to be given to children below the age of two years with SMA.
     
  • The FDA acknowledged that there were data integrity issues with Zolgensma’s Biologics License Application.

The U.S. Food and Drug Administration, (FDA), recently announced a statement that there were data integration problems with Zolgensma’s Biologics License Applications (BLA). Meanwhile, the company stated that it is wholly confident about efficacy, quality, and safety of Zolgensma for treating spinal muscular atrophy (SMA) in children below the age of two years.

The FDA still supports the continued use and marketing of Zolgensma for patients with SMA. Novartis continues to be steadfast about this crucial treatment being readily available to pediatric patients with SMA. The company maintains complete evidence, that demonstrates effectiveness of the product and the safety profile, continues to provide convincing proof that backs the drug’s favorable benefit-risk profile.

Reports cite, that previously AveXis voluntarily disclosed to FDA and other authorities that some data presented earlier, as part of its BLA package, was inaccurate. Avexis became aware of data manipulation allegations in a specific animal testing process used during product development. The assessments in questions were taken for primary product testing and presently are not utilized for commercial product release.

This resulted in an immediate investigation to quickly find inferences and accordingly address the situation. Once Novartis had some interim conclusions, it shared its observations with FDA. As acknowledged by FDA, the data was a small portion of the company’s overall submission and was in an older process that is no more used.

According to Novartis, throughout the investigation, findings didn’t show any problems with quality, efficacy, or safety of the product. The company remains completely capable of facilitating fully compliant, high quality Zolgensma to patients.

Novartis has and will continue to work with FDA to update its submission and identify the quality gaps. Novartis is committed to make sure the greatest levels of integrity and transparency with health agencies and patients.

 

Source Credit:

https://www.novartis.com/news/media-releases/novartis-stands-behind-zolgensma-onasemnogene-abeparvovec-xioi-treatment-children-less-2-years-age-spinal-muscular-atrophy

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...